Pozen sells Treximet royalties for $75M, bolstering partnering for PhIII CV drug
This article was originally published in Scrip
Executive Summary
The US company Pozen has sold most of the future US royalty and milestone rights associated with its migraine drug Treximet (sumatriptan/naproxen sodium) to Canada’s national pension fund CPPIB Credit Investments (CCI) for $75 million. The move provides the company a more solid cash position as it seeks partners for its promising investigational candidate in Phase III trials, PA32540.